Mirapexin (Pramipexole)
Dopamine agonist for Parkinson's disease and restless legs syndrome
Mirapexin contains the active substance pramipexole, a non-ergot dopamine agonist that stimulates dopamine receptors in the brain. It is primarily prescribed for the treatment of Parkinson's disease and moderate to severe idiopathic restless legs syndrome (RLS). Mirapexin is available as immediate-release tablets taken three times daily and prolonged-release tablets taken once daily. This medication requires a prescription and should only be used under medical supervision.
Quick Facts
Key Takeaways
- Mirapexin (pramipexole) is a dopamine agonist used to treat Parkinson's disease and moderate to severe restless legs syndrome (RLS)
- Available as immediate-release tablets (taken 3 times daily) and prolonged-release tablets (taken once daily) for convenient dosing
- Must be gradually titrated up when starting and slowly tapered when stopping to avoid withdrawal symptoms
- Can cause sudden onset of sleep without warning, so patients should not drive or operate machinery until they know how the medication affects them
- Impulse control disorders (gambling, hypersexuality, compulsive spending) are a recognized risk that patients and caregivers should monitor for
What Is Mirapexin and What Is It Used For?
Quick Answer: Mirapexin contains pramipexole, a dopamine agonist that mimics the action of dopamine in the brain. It is prescribed for Parkinson's disease (to reduce motor symptoms such as tremor, stiffness, and slowness) and for moderate to severe restless legs syndrome (RLS), a condition causing uncomfortable sensations and an irresistible urge to move the legs.
Mirapexin belongs to a class of medications known as dopamine agonists. These drugs work by directly stimulating dopamine receptors in the brain, particularly the D2 family of receptors, with a preferential affinity for the D3 receptor subtype. In Parkinson's disease, the neurons that produce dopamine in a brain region called the substantia nigra progressively degenerate. By stimulating the remaining dopamine receptors, pramipexole helps compensate for this deficiency and improves motor function.
In Parkinson's disease, Mirapexin can be used as monotherapy in the early stages of the condition, or in combination with levodopa (the gold standard treatment for Parkinson's disease) in more advanced stages. When used alongside levodopa, pramipexole often allows patients to take lower doses of levodopa, which can reduce levodopa-related motor complications such as dyskinesia (involuntary movements) and the "on-off" phenomenon where the effect of levodopa wears off unpredictably.
For restless legs syndrome (RLS), also known as Willis-Ekbom disease, Mirapexin is indicated for moderate to severe idiopathic cases. RLS is characterized by uncomfortable sensations in the legs (and sometimes arms) that typically occur during periods of rest or inactivity, particularly in the evening and at night. The exact mechanism by which pramipexole alleviates RLS symptoms is not fully understood, but it is believed to involve modulation of the dopaminergic pathways in the central nervous system. Mirapexin has been shown in clinical trials to significantly reduce RLS symptom severity and improve sleep quality.
Pramipexole is classified as a non-ergot dopamine agonist, distinguishing it from older ergot-derived dopamine agonists such as bromocriptine and cabergoline. Non-ergot dopamine agonists carry a lower risk of fibrotic complications (such as cardiac valve fibrosis and retroperitoneal fibrosis) compared to their ergot-derived counterparts. This safety advantage has made non-ergot dopamine agonists like pramipexole the preferred choice within this drug class.
What Should You Know Before Taking Mirapexin?
Quick Answer: Before taking Mirapexin, inform your doctor about all medical conditions, especially kidney problems, heart disease, or a history of psychotic episodes or impulse control disorders. Mirapexin is not recommended during pregnancy or breastfeeding. It can interact with several medications including antipsychotics, metoclopramide, and drugs that affect kidney function.
Contraindications
Mirapexin should not be taken if you are allergic to pramipexole or any of the other ingredients in the tablets. If you have previously experienced an allergic reaction to pramipexole, you should inform your doctor immediately and an alternative treatment will be considered.
Tell your doctor if you experience any unusual urges or behaviors such as gambling, excessive spending, binge eating, or increased sexual drive. These impulse control disorders can develop during treatment with Mirapexin and may require dose adjustment or discontinuation.
Warnings and Precautions
Before and during treatment with Mirapexin, you should discuss the following with your doctor:
- Kidney problems (renal impairment): Pramipexole is primarily eliminated through the kidneys. Patients with reduced kidney function may require lower doses and more frequent monitoring. Your doctor will assess your kidney function before starting treatment and adjust the dose accordingly. In severe renal impairment (creatinine clearance below 20 mL/min), Mirapexin is generally not recommended.
- Hallucinations and psychotic episodes: Dopamine agonists can cause hallucinations (seeing, hearing, or feeling things that are not there), delusions, and other psychotic symptoms. These are more common in elderly patients and those with advanced Parkinson's disease. If you experience hallucinations, contact your doctor promptly.
- Sudden onset of sleep: Pramipexole can cause excessive daytime sleepiness and episodes of sudden sleep onset, sometimes without prior warning or feeling of drowsiness. This can occur at any time during treatment. Do not drive vehicles or operate machinery until you are confident that Mirapexin does not affect your alertness.
- Orthostatic hypotension: Mirapexin can cause a drop in blood pressure when standing up from a sitting or lying position, leading to dizziness, lightheadedness, or fainting. This is particularly common during the initial dose-titration period. Rise slowly from a sitting or lying position to minimize this effect.
- Augmentation (RLS patients): In patients with RLS, long-term treatment with dopamine agonists can lead to augmentation, a worsening of symptoms that may occur earlier in the day, spread to other body parts, or become more intense. If this occurs, your doctor may adjust your treatment.
- Dopamine dysregulation syndrome: Some patients, particularly those with Parkinson's disease, may develop compulsive overuse of their dopaminergic medications. This can lead to excessive medication intake despite developing harmful side effects.
- Eye examinations: Regular ophthalmological examinations are recommended during treatment, as dopamine agonists may affect vision.
Pregnancy and Breastfeeding
Mirapexin is not recommended during pregnancy. While animal studies have not shown direct teratogenic effects, there are insufficient data on the use of pramipexole in pregnant women. If you are pregnant, planning to become pregnant, or discover that you are pregnant during treatment, contact your doctor immediately. Women of childbearing potential should use reliable contraception throughout treatment.
Mirapexin should not be used during breastfeeding. Pramipexole inhibits the secretion of prolactin, the hormone responsible for milk production, and may therefore reduce or suppress lactation. It is not known whether pramipexole passes into breast milk. If treatment with Mirapexin is considered essential, breastfeeding should be discontinued.
Mirapexin may cause drowsiness, dizziness, and sudden sleep episodes. Patients should not drive, ride a bicycle, or operate machinery until they have gained enough experience with Mirapexin to assess whether it affects their ability to perform these activities safely. Patients should be advised that if they experience excessive sedation or sudden sleep episodes, they should refrain from driving and contact their doctor.
How Does Mirapexin Interact with Other Drugs?
Quick Answer: Mirapexin can interact with antipsychotic drugs, metoclopramide, cimetidine, amantadine, and other medications that affect dopamine or kidney function. Antipsychotics are the most significant interaction as they can reduce the effectiveness of pramipexole. Always inform your doctor about all medications you are taking.
Pramipexole is primarily eliminated unchanged by the kidneys via tubular secretion. Any medication that inhibits renal tubular secretion or is itself secreted via this pathway may potentially interact with pramipexole by increasing its blood levels. The most clinically significant drug interactions are described below.
Major Interactions
The following interactions are considered clinically significant and may require dose adjustments or alternative treatments:
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Antipsychotics (e.g., haloperidol, chlorpromazine, risperidone, quetiapine) | Block dopamine receptors, directly opposing the mechanism of pramipexole | Avoid combination if possible. If antipsychotics are necessary, clozapine or quetiapine (at lowest effective dose) may be preferred in Parkinson's patients |
| Metoclopramide | A dopamine antagonist that may reduce pramipexole effectiveness and worsen Parkinsonian symptoms | Avoid this combination. Use domperidone or ondansetron as alternative antiemetics |
| Cimetidine | Inhibits renal tubular secretion, increasing pramipexole plasma levels by approximately 50% | Consider dose reduction of pramipexole or use an alternative H2 antagonist (e.g., ranitidine) |
| Amantadine | Also excreted via renal tubular secretion; mutual increase in plasma levels possible | Monitor for increased side effects of both drugs. Dose adjustment may be necessary |
Other Interactions to Be Aware Of
The following interactions are less common but should be mentioned to your doctor:
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Levodopa | Mutual enhancement of dopaminergic effects; increased risk of dyskinesia | Levodopa dose reduction may be needed when adding pramipexole. This is an expected and managed combination |
| Sedatives, alcohol | Additive sedation; increased risk of drowsiness and sudden sleep | Limit alcohol intake. Use caution with benzodiazepines, opioids, and antihistamines |
| Other dopamine agonists | Additive dopaminergic stimulation; increased risk of side effects | Generally avoid combining multiple dopamine agonists |
| Anticholinergics | No direct pharmacokinetic interaction, but additive cognitive effects possible | Monitor cognitive function, especially in elderly patients |
Pramipexole has low plasma protein binding (less than 20%) and is not significantly metabolized by cytochrome P450 enzymes. This means it has a relatively low potential for pharmacokinetic interactions with drugs that affect liver metabolism. However, always inform your doctor and pharmacist about all medications you take, including over-the-counter medicines and herbal supplements.
What Is the Correct Dosage of Mirapexin?
Quick Answer: Dosage of Mirapexin is individualized and must be gradually increased (titrated) over several weeks. For Parkinson's disease, the starting dose is typically 0.264 mg/day (immediate-release) or 0.26 mg once daily (prolonged-release), increased every 5-7 days. For restless legs syndrome, the starting dose is 0.088 mg once daily, taken 2-3 hours before bedtime.
Mirapexin dosing must be carefully individualized by your doctor. The dose is expressed in terms of pramipexole base. Immediate-release tablets are taken three times daily with or without food, while prolonged-release tablets are taken once daily, swallowed whole without chewing or crushing. Treatment always begins with a low dose that is gradually increased to find the optimal balance between symptom control and side effects.
Parkinson's Disease — Immediate-Release Tablets
Dose Titration Schedule
| Week | Single Dose | Total Daily Dose |
|---|---|---|
| Week 1 | 0.088 mg three times daily | 0.264 mg |
| Week 2 | 0.18 mg three times daily | 0.54 mg |
| Week 3 | 0.35 mg three times daily | 1.1 mg |
| Maintenance | 0.35 – 1.1 mg three times daily | 1.1 – 3.3 mg |
If a further dose increase is necessary, the daily dose should be increased by 0.54 mg per week, up to a maximum of 3.3 mg per day. The effective maintenance dose in most patients is between 1.1 mg and 3.3 mg per day divided into three doses.
Parkinson's Disease — Prolonged-Release Tablets
Once-Daily Dosing
Prolonged-release tablets are taken once daily at approximately the same time each day. The starting dose is 0.26 mg once daily, with increases at weekly intervals up to a maximum of 3.15 mg once daily. The same total daily doses apply, but the convenience of once-daily dosing can improve patient adherence and provide smoother symptom control throughout the day.
Restless Legs Syndrome
RLS Dosing Schedule
| Period | Daily Dose | Timing |
|---|---|---|
| Weeks 1-2 | 0.088 mg | 2-3 hours before bedtime |
| Weeks 3-4 (if needed) | 0.18 mg | 2-3 hours before bedtime |
| Week 5+ (if needed) | 0.35 mg | 2-3 hours before bedtime |
| Maximum dose | 0.54 mg | 2-3 hours before bedtime |
For RLS, the tablet is taken as a single dose 2 to 3 hours before bedtime. The need for continued treatment should be reassessed every 3 months by your doctor. If treatment is interrupted for more than a few days, it should be re-initiated at the lowest dose and re-titrated upward.
Elderly Patients
No specific dose adjustment is required for elderly patients with normal kidney function. However, elderly patients may be more susceptible to side effects such as hallucinations, orthostatic hypotension, and excessive drowsiness. The dose should be increased cautiously, and lower maintenance doses may be appropriate. Regular monitoring of kidney function is recommended in elderly patients, as age-related decline in renal function is common.
Renal Impairment
Because pramipexole is eliminated primarily through the kidneys, dose reductions are necessary in patients with impaired renal function. Your doctor will adjust the dose based on creatinine clearance. Patients with moderate impairment (creatinine clearance 20-50 mL/min) typically start at a lower dose and increase more slowly. In severe impairment (creatinine clearance below 20 mL/min), treatment with pramipexole is generally not recommended.
Missed Dose
If you miss a dose of immediate-release Mirapexin, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for the missed one. For prolonged-release tablets, if you miss a dose, take it as soon as you remember on the same day. If a full day has passed, do not take a double dose the following day.
Overdose
There is no specific antidote for pramipexole overdose. Symptoms of overdose may include nausea, vomiting, agitation, restlessness, excessive involuntary movements (hyperkinesia), hallucinations, and severe hypotension. If overdose is suspected, contact your local poison control center or emergency services immediately. Treatment is supportive, and gastric lavage, activated charcoal, intravenous fluids, and cardiac monitoring may be indicated. Since pramipexole is not significantly removed by dialysis, hemodialysis is unlikely to be helpful.
What Are the Side Effects of Mirapexin?
Quick Answer: The most common side effects of Mirapexin include nausea, dizziness, drowsiness, insomnia, constipation, hallucinations, and dyskinesia (when used with levodopa). Serious but less common effects include sudden sleep attacks, severe hypotension, impulse control disorders, and dopamine agonist withdrawal syndrome when stopping.
Like all medicines, Mirapexin can cause side effects, although not everybody gets them. The frequency and type of side effects may differ depending on whether pramipexole is used for Parkinson's disease or for restless legs syndrome. Many side effects are dose-dependent and can be reduced by gradual dose titration. Inform your doctor if any side effects become troublesome or persistent.
Very Common
- Dyskinesia (involuntary movements; in Parkinson's patients on levodopa)
- Somnolence (excessive drowsiness)
- Dizziness
- Nausea
Common
- Impulse control disorders (pathological gambling, compulsive eating, hypersexuality, compulsive shopping)
- Hallucinations (seeing or hearing things that are not real)
- Insomnia
- Abnormal dreams and nightmares
- Headache
- Confusion
- Constipation
- Vomiting
- Hypotension (low blood pressure)
- Fatigue
- Peripheral oedema (swelling of ankles/feet)
- Weight loss or weight gain
- Visual disturbances including blurred vision
Uncommon
- Paranoia
- Delusional thinking
- Excessive daytime sleepiness with sudden sleep onset
- Amnesia (memory loss)
- Hyperkinesia (excessive movement)
- Dyspnoea (shortness of breath)
- Hiccups
- Pneumonia (in very elderly or debilitated patients)
- Inappropriate secretion of antidiuretic hormone (SIADH)
Rare
- Mania (extremely elevated mood)
- Dopamine dysregulation syndrome (compulsive medication overuse)
- Severe skin reactions
- Rhabdomyolysis (muscle breakdown; usually associated with neuroleptic malignant syndrome)
Patients taking Mirapexin may experience behavioral changes including pathological gambling, increased libido and hypersexuality, compulsive spending or shopping, and binge or compulsive eating. These behaviors can be severe and harmful. Patients and their caregivers should be aware of these potential effects and report any behavioral changes to their doctor immediately. Risk factors include a personal or family history of impulse control problems and higher doses of the medication.
When stopping Mirapexin, particularly after long-term use, some patients develop withdrawal symptoms including apathy, anxiety, depression, fatigue, sweating, and pain. This syndrome is known as DAWS and can occur even with gradual dose reduction. Symptoms may last weeks to months. If you experience withdrawal symptoms, discuss treatment options with your doctor. The dose should always be tapered gradually, never stopped abruptly.
How Should You Store Mirapexin?
Quick Answer: Store Mirapexin at room temperature below 25°C (77°F), protected from light. Keep in the original packaging. Store out of the sight and reach of children. Do not use after the expiry date printed on the carton and blister.
Proper storage of Mirapexin is important to ensure the medication remains effective and safe to use throughout its shelf life. Follow these guidelines:
- Temperature: Store below 25°C (77°F). Do not refrigerate or freeze.
- Light protection: Keep the tablets in the original blister packaging to protect them from light exposure, which can degrade the active ingredient over time.
- Moisture: Store in a dry place. Do not remove tablets from the blister packaging until you are ready to take them.
- Child safety: Keep this medicine out of the sight and reach of children. Use a child-resistant storage location.
- Expiry date: Do not use Mirapexin after the expiry date stated on the carton and blister (marked "EXP"). The expiry date refers to the last day of that month.
- Disposal: Do not dispose of medicines via household waste or wastewater. Return unused or expired tablets to your pharmacy for proper disposal. This helps protect the environment.
If you notice any change in the appearance of the tablets (discoloration, crumbling, or unusual odor), do not use them and consult your pharmacist for a replacement.
What Does Mirapexin Contain?
Quick Answer: The active ingredient in Mirapexin is pramipexole dihydrochloride monohydrate. The tablets also contain inactive ingredients (excipients) such as mannitol, maize starch, colloidal anhydrous silica, povidone, and magnesium stearate. Prolonged-release tablets additionally contain hypromellose and carbomer for the sustained-release mechanism.
Active Ingredient
The active substance is pramipexole dihydrochloride monohydrate. The strength of each tablet is expressed as pramipexole base equivalent. For example:
- 0.088 mg pramipexole base = 0.125 mg pramipexole dihydrochloride monohydrate
- 0.18 mg pramipexole base = 0.25 mg pramipexole dihydrochloride monohydrate
- 0.26 mg pramipexole base = 0.375 mg pramipexole dihydrochloride monohydrate (prolonged-release)
- 0.35 mg pramipexole base = 0.5 mg pramipexole dihydrochloride monohydrate
- 0.7 mg pramipexole base = 1.0 mg pramipexole dihydrochloride monohydrate
- 1.1 mg pramipexole base = 1.5 mg pramipexole dihydrochloride monohydrate
Inactive Ingredients (Excipients)
Immediate-release tablets: Mannitol, maize starch, colloidal anhydrous silica, povidone K25, and magnesium stearate. These excipients help form the tablet structure, aid in disintegration and absorption, and ensure manufacturing consistency.
Prolonged-release tablets: In addition to the above, these tablets contain hypromellose 2208 and carbomer 941, which form a gel matrix that slowly releases pramipexole over a 24-hour period. This allows once-daily dosing instead of three times daily.
Mirapexin tablets are scored, making them easy to divide for dose adjustment. The different strengths are distinguished by their shape and markings. None of the tablet formulations contain lactose, gluten, or sucrose, making them suitable for patients with common dietary intolerances.
Frequently Asked Questions About Mirapexin
Mirapexin (pramipexole) is a dopamine agonist used to treat two main conditions: Parkinson's disease (both as monotherapy in early stages and in combination with levodopa in advanced disease) and moderate to severe restless legs syndrome (RLS). It works by stimulating dopamine receptors in the brain, helping to compensate for low dopamine levels. In Parkinson's disease, it reduces tremor, stiffness, and slowness of movement. In RLS, it alleviates the uncomfortable sensations and urge to move the legs that typically worsen at rest and in the evening.
The most common side effects include nausea, dizziness, drowsiness (somnolence), and involuntary movements (dyskinesia, when used with levodopa). Sudden sleep onset can occur without warning. Impulse control disorders such as pathological gambling, compulsive eating, or hypersexuality affect some patients. Orthostatic hypotension (low blood pressure when standing) is also common, especially at the start of treatment. Many of these side effects improve over time or with dose adjustment.
No. Mirapexin must be tapered gradually under medical supervision. Abrupt discontinuation can trigger dopamine agonist withdrawal syndrome (DAWS) with symptoms including anxiety, panic attacks, depression, sweating, nausea, pain, and fatigue. In rare cases, stopping suddenly can cause a condition resembling neuroleptic malignant syndrome. Your doctor will typically reduce the dose gradually over one to two weeks. Always consult your doctor before making any changes to your dosing schedule.
Standard Mirapexin tablets (immediate-release) are taken three times daily and release the active ingredient quickly. Mirapexin prolonged-release tablets are taken once daily and release pramipexole slowly over 24 hours, providing more stable blood levels throughout the day. Both formulations are equally effective, but the prolonged-release version offers greater convenience and may reduce fluctuations in symptom control. You should not switch between formulations without your doctor's guidance, as the dosing schedules and individual tablet strengths differ.
Yes, impulse control disorders are a recognized side effect of all dopamine agonists, including Mirapexin. These can include pathological gambling, increased libido and hypersexuality, compulsive spending or shopping, and binge eating. These behaviors may be severe and potentially harmful to the patient and their family. Patients and caregivers should monitor for any unusual behavioral changes and report them promptly to the prescribing doctor. Risk factors include a personal or family history of impulse control issues and higher medication doses. If impulse control disorders develop, dose reduction or discontinuation may be necessary.
Mirapexin is not recommended during pregnancy. While animal studies have not shown direct harmful effects on fetal development, there is insufficient data in pregnant women to confirm safety. Pramipexole also inhibits prolactin secretion, which may affect breastfeeding. Women of childbearing age should use adequate contraception while taking Mirapexin. If you become pregnant or are planning a pregnancy, contact your doctor immediately to discuss the risks and benefits and to consider alternative treatments.
References
This article is based on the following peer-reviewed sources and international guidelines:
- European Medicines Agency (EMA). Mirapexin Summary of Product Characteristics. Last updated 2024. Available at: EMA Mirapexin EPAR.
- National Institute for Health and Care Excellence (NICE). Parkinson's disease in adults: diagnosis and management. NICE Guideline NG71, updated 2024.
- Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Movement Disorders. 2018;33(8):1248-1266.
- Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-Foundation. Sleep Medicine. 2016;21:1-11.
- Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurology. 2007;6(9):826-829.
- Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Archives of Neurology. 2010;67(5):589-595.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List, 2023.
- British National Formulary (BNF). Pramipexole monograph. Updated 2025.
- Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. European Journal of Neurology. 2013;20(1):5-15.
- Trenkwalder C, Allen R, Högl B, et al. Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurology. 2018;17(11):994-1005.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians with expertise in neurology, movement disorders, and clinical pharmacology.
Written by specialist physicians with clinical experience in neurology and movement disorder pharmacotherapy. Content follows the GRADE evidence framework and international treatment guidelines.
Independently reviewed by the iMedic Medical Review Board. All medical claims verified against EMA SmPC, NICE guidelines, and peer-reviewed literature. No commercial funding or pharmaceutical sponsorship.